联用脂必泰和阿托伐他汀对冠心病患者血脂及炎症因子的影响
|
摘要
目的：通过对脂必泰和阿托伐他汀10mg联用与单独使用阿托伐他汀20mg、阿托伐他汀40mg进行对比研究,观察各组的降脂疗效、对冠心病患者炎症因子促心肌素(CT-1)、高敏C反应蛋白(hs-CRP)的影响及不良反应,评价脂必泰和阿托伐他汀10mg联用对冠心病患者的临床降脂、抗炎疗效及其临床应用安全性。为脂必泰和阿托伐他汀联合应用提供临床参考依据,为冠心病的治疗提供新的思路和策略。
方法：选取150例符合临床诊断标准的冠心病患者,所有患者均在基本药物治疗下进行随机分组,平均分为3组。1组予以脂必泰胶囊480mg,每日分两次口服+阿托伐他汀钙10mg,每晚睡前半小时服用1次,连用8周；2组予以阿托伐他汀钙20mg口服,每晚睡前半小时服用1次,连用8周；3组予以阿托伐他汀钙40mg口服,每晚睡前半小时服用1次,连用8周。
基本药物治疗指：所有入组的冠心病患者依据病情给予下列药物：血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)、钙离子拮抗剂(CCB)、氯吡格雷、拜阿司匹林、β受体阻滞剂、欣康片(单硝酸异山梨酯片)以及其它相应的降压、降糖等治疗。
所有患者分别于治疗前、治疗后4周、8周清晨空腹抽取外周静脉血,分离血清检测CT-1 hs-CRP浓度。
所有患者均于治疗前、治疗后4周、8周清晨空腹抽取外周静脉血,分离血清检测血脂谱：甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(ApoA1)、载脂蛋白B100 (ApoB100)。同时检测肝功能指标：谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、直接胆红素(DBIL)；肾功能指标：尿素氮(BUN)、肌酐(Cr)；肌酶谱：肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)、肌钙蛋白(aTn-I)、肌红蛋白(MYO)。
所有患者入院后行常规12导联心电图(ECG)检查。
结果：
1、与治疗前相比,三组患者经治疗4周、8周后,血清TC、LDL-C、ApoB100浓度均显著下降,均具有统计学差异(所有P<0.01)。其中脂必泰+阿托伐他汀10mg组与阿托伐他汀40mg组疗效近似,二者较阿托伐他汀20mg组略有优势,但组间比较无统计学差异(P>0.05)。
2、与治疗前相比,三组患者经治疗4周、8周后TG均下降,脂必泰+阿托伐他汀10mg组与阿托伐他汀40mg组治疗4周、8周后TG明显下降(所有P<0.01),脂必泰+阿托伐他汀10mg组TG下降更明显；阿托伐他汀20mg组治疗4周后TG无明显下降(P>0.05),治疗8周后TG显著下降(P<0.01),治疗8周后三组间比较无统计学差异(P>0.05)。
3、与治疗前相比,三组患者经治疗4周、8周后HDL-C.ApOA1水平有所升高,但无统计学差异(所有P>0.05),组间比较亦无差异(P>0.05)。
4、与治疗前相比,三组患者治疗4周、8周后炎症因子CT-1、hs-CRP均显著下降(P<0.01),脂必泰+阿托伐他汀10mg组与阿托伐他汀40mg组较阿托伐他汀20mg组下降更为明显,但组问比较无统计学差异(P>0.05)。
5、与治疗前相比,三组患者治疗4周、8周后肝功能、肾功能、肌病发生率、肌酶升高发生率、消化道不良反应发生率均无统计学差异(P>0.05),组间比较无统计学差异(P>0.05)。
结论：脂必泰与阿托伐他汀10mg联用可以明显降低冠心病患者TG、TC、LDL-C、ApoB100水平,轻度升高HDL-C、ApoA1水平,并显著降低炎症因子CT-1、hs-CRP水平,疗效与阿托伐他汀40mg相仿,较阿托伐他汀20mg具有优势,而且副作用小,临床应用安全,可望成为今后降脂治疗的新趋势。
Objective:By discuss zhibitai combined with atorvastatin 10mg and only use atorvastatin 20mg or atorvastatin 40mg, we well evaluate the clinical lipid-lowering, anti-inflammatory effect and clinical app-lication security of zhibitai combined with atorvastatin 10mg by comparing the lipid-lowering effects of observed in each group myo-cardial inflammatory factors of carditrophin-1 (CT-1),high sen-sitivity creactive protein (hs-CRP) and adverse effects in patients with coronary heart disease.The result will provide clinical reference applications and provide new ideas and strategies for zhibitai combined with atorvastatin in coronary heart disease
Methods:150 patients with clinical diagnostic criteria for coronary heart disease patients, all patients were divided into 3 groups under medical treatment in the basic randomized. Group 1 to zhibitai 480 mg, orally twice daily+atorvastatin calcium 10mg, taken a half an hour before going to bed every night, once every 8 weeks, once every 8 weeks; 2 groups to atorvastatin calcium 20mg taken a half an hour before going to bed every night, once every 8 weeks, once every 8 weeks; 3 groups to atorvastatin calcium 40mg orally, taken a half an hour before going to bed every night, once every 8 weeks.
Basic medical treatment means:all entry groups to give patients with coronary heart disease based on the following drugs:angioten-sin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), calcium channel blockers (CCB), Clopidogrel, Aspirin,βblockers, Zhixinkang tablets (isosorbide mononitrate tablets) and other appropriate blood pressure, glucose and other treat ment.
All patients test the concentration of CT-1 and hs-CRP in the serum separating from venous blood in before treatment, after 4 weeks and after 8 weeks.
All patients test the lipoprotein profile:triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low-density lipoprotein choles-terol (LDL-C), apolipoprotein A1 (ApoA1) and apolipoprotein B100(ApoB100).Simultaneous test liver function:alanine aminotransferase (ALT), aspartate amino trans-ferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL); renal function:urea ni-trogen (BUN), creatinine (Cr); muscle enzymes: creatine kinase (CK), creatine kinase isoenzyme MB (CK-MB), troponin (aTn-I), myoglobin (MYO) in the serum separating from venous blood in before treatment, after 4 weeks and after 8 weeks.
All patients test 12-lead electrocardio-gram (ECG) examina-tion after hospitalization.
Results:
1、compared with before treatment, the levels of TC, LDL-C, ApoB100 in three groups were significantly decreased after 4 weeks and 8 weeks (all P<0.01). Zhibitai+atorvastatin 100mg group and atorvastatin 40mg group have similar efficacy, both groups had slight advantage than atorvastatin 20mg group,but no significant difference between the two groups (P> 0.05).
2、compared with before treatment, the levels of TG in three groups of patients were decreased, zhibitai+ atorvastatin 10mg group and atorvastatin 40mg group decreased more significantly than atorvas-tatin 20mg group, atorvastatin 20mg group had no significant decrease after treatment 4 weeks (P> 0.05), after 8 weeks treatment decreased significantly (P<0.01), no significant difference between the three groups after treatmeat for 8 weeks. (P> 0.05)
3、compared with before treatment, the levels of HDL-C and ApoA1 in three groups of patients were increased after 4 weeks and 8 weeks, but no significant differences (all P> 0.05), no difference between the three groups (P> 0.05).
4、compared with before treatment, the levels of CT-1 and hs-CRP were significantly decreased in three groups of patients treated for after 4 weeks and 8 weeks (P<0.01), zhibitai+ atorvastatin 10mg group and atorvastatin 40mg group decreased more significantly than atorvastatin 20mg group, no significant difference between the three groups (P> 0.05).
5、compared with before treatment, the levels of liver function, kidney function, the incidence of myopathy, muscle enzyme increased incidence and gastrointestinal adverse reactions in three groups of patients was no significant difference in the incidence rate after treated 4 weeks and 8 weeks (P> 0.05), no significant differen-ce between the three groups (P> 0.05).
Conclusion:Zhibitai combined with atorvastatin lOmg in patients with coronary heart disease can be significantly reduced TG, TC, LDL-C, ApoB100 level, slightly elevated HDL-C, ApoA1 levels and significantly reduce the inflammatory cytokines CT-1, hs-CRP levels, efficacy and similar atorvastatin 40mg, atorvastatin 20mg compared with more advantages and fewer side effects, clinical application security, is expected to become the new trend for future lipid-lowering therapy.
方法：选取150例符合临床诊断标准的冠心病患者,所有患者均在基本药物治疗下进行随机分组,平均分为3组。1组予以脂必泰胶囊480mg,每日分两次口服+阿托伐他汀钙10mg,每晚睡前半小时服用1次,连用8周；2组予以阿托伐他汀钙20mg口服,每晚睡前半小时服用1次,连用8周；3组予以阿托伐他汀钙40mg口服,每晚睡前半小时服用1次,连用8周。
基本药物治疗指：所有入组的冠心病患者依据病情给予下列药物：血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)、钙离子拮抗剂(CCB)、氯吡格雷、拜阿司匹林、β受体阻滞剂、欣康片(单硝酸异山梨酯片)以及其它相应的降压、降糖等治疗。
所有患者分别于治疗前、治疗后4周、8周清晨空腹抽取外周静脉血,分离血清检测CT-1 hs-CRP浓度。
所有患者均于治疗前、治疗后4周、8周清晨空腹抽取外周静脉血,分离血清检测血脂谱：甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(ApoA1)、载脂蛋白B100 (ApoB100)。同时检测肝功能指标：谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、直接胆红素(DBIL)；肾功能指标：尿素氮(BUN)、肌酐(Cr)；肌酶谱：肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)、肌钙蛋白(aTn-I)、肌红蛋白(MYO)。
所有患者入院后行常规12导联心电图(ECG)检查。
结果：
1、与治疗前相比,三组患者经治疗4周、8周后,血清TC、LDL-C、ApoB100浓度均显著下降,均具有统计学差异(所有P<0.01)。其中脂必泰+阿托伐他汀10mg组与阿托伐他汀40mg组疗效近似,二者较阿托伐他汀20mg组略有优势,但组间比较无统计学差异(P>0.05)。
2、与治疗前相比,三组患者经治疗4周、8周后TG均下降,脂必泰+阿托伐他汀10mg组与阿托伐他汀40mg组治疗4周、8周后TG明显下降(所有P<0.01),脂必泰+阿托伐他汀10mg组TG下降更明显；阿托伐他汀20mg组治疗4周后TG无明显下降(P>0.05),治疗8周后TG显著下降(P<0.01),治疗8周后三组间比较无统计学差异(P>0.05)。
3、与治疗前相比,三组患者经治疗4周、8周后HDL-C.ApOA1水平有所升高,但无统计学差异(所有P>0.05),组间比较亦无差异(P>0.05)。
4、与治疗前相比,三组患者治疗4周、8周后炎症因子CT-1、hs-CRP均显著下降(P<0.01),脂必泰+阿托伐他汀10mg组与阿托伐他汀40mg组较阿托伐他汀20mg组下降更为明显,但组问比较无统计学差异(P>0.05)。
5、与治疗前相比,三组患者治疗4周、8周后肝功能、肾功能、肌病发生率、肌酶升高发生率、消化道不良反应发生率均无统计学差异(P>0.05),组间比较无统计学差异(P>0.05)。
结论：脂必泰与阿托伐他汀10mg联用可以明显降低冠心病患者TG、TC、LDL-C、ApoB100水平,轻度升高HDL-C、ApoA1水平,并显著降低炎症因子CT-1、hs-CRP水平,疗效与阿托伐他汀40mg相仿,较阿托伐他汀20mg具有优势,而且副作用小,临床应用安全,可望成为今后降脂治疗的新趋势。
Objective:By discuss zhibitai combined with atorvastatin 10mg and only use atorvastatin 20mg or atorvastatin 40mg, we well evaluate the clinical lipid-lowering, anti-inflammatory effect and clinical app-lication security of zhibitai combined with atorvastatin 10mg by comparing the lipid-lowering effects of observed in each group myo-cardial inflammatory factors of carditrophin-1 (CT-1),high sen-sitivity creactive protein (hs-CRP) and adverse effects in patients with coronary heart disease.The result will provide clinical reference applications and provide new ideas and strategies for zhibitai combined with atorvastatin in coronary heart disease
Methods:150 patients with clinical diagnostic criteria for coronary heart disease patients, all patients were divided into 3 groups under medical treatment in the basic randomized. Group 1 to zhibitai 480 mg, orally twice daily+atorvastatin calcium 10mg, taken a half an hour before going to bed every night, once every 8 weeks, once every 8 weeks; 2 groups to atorvastatin calcium 20mg taken a half an hour before going to bed every night, once every 8 weeks, once every 8 weeks; 3 groups to atorvastatin calcium 40mg orally, taken a half an hour before going to bed every night, once every 8 weeks.
Basic medical treatment means:all entry groups to give patients with coronary heart disease based on the following drugs:angioten-sin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), calcium channel blockers (CCB), Clopidogrel, Aspirin,βblockers, Zhixinkang tablets (isosorbide mononitrate tablets) and other appropriate blood pressure, glucose and other treat ment.
All patients test the concentration of CT-1 and hs-CRP in the serum separating from venous blood in before treatment, after 4 weeks and after 8 weeks.
All patients test the lipoprotein profile:triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low-density lipoprotein choles-terol (LDL-C), apolipoprotein A1 (ApoA1) and apolipoprotein B100(ApoB100).Simultaneous test liver function:alanine aminotransferase (ALT), aspartate amino trans-ferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL); renal function:urea ni-trogen (BUN), creatinine (Cr); muscle enzymes: creatine kinase (CK), creatine kinase isoenzyme MB (CK-MB), troponin (aTn-I), myoglobin (MYO) in the serum separating from venous blood in before treatment, after 4 weeks and after 8 weeks.
All patients test 12-lead electrocardio-gram (ECG) examina-tion after hospitalization.
Results:
1、compared with before treatment, the levels of TC, LDL-C, ApoB100 in three groups were significantly decreased after 4 weeks and 8 weeks (all P<0.01). Zhibitai+atorvastatin 100mg group and atorvastatin 40mg group have similar efficacy, both groups had slight advantage than atorvastatin 20mg group,but no significant difference between the two groups (P> 0.05).
2、compared with before treatment, the levels of TG in three groups of patients were decreased, zhibitai+ atorvastatin 10mg group and atorvastatin 40mg group decreased more significantly than atorvas-tatin 20mg group, atorvastatin 20mg group had no significant decrease after treatment 4 weeks (P> 0.05), after 8 weeks treatment decreased significantly (P<0.01), no significant difference between the three groups after treatmeat for 8 weeks. (P> 0.05)
3、compared with before treatment, the levels of HDL-C and ApoA1 in three groups of patients were increased after 4 weeks and 8 weeks, but no significant differences (all P> 0.05), no difference between the three groups (P> 0.05).
4、compared with before treatment, the levels of CT-1 and hs-CRP were significantly decreased in three groups of patients treated for after 4 weeks and 8 weeks (P<0.01), zhibitai+ atorvastatin 10mg group and atorvastatin 40mg group decreased more significantly than atorvastatin 20mg group, no significant difference between the three groups (P> 0.05).
5、compared with before treatment, the levels of liver function, kidney function, the incidence of myopathy, muscle enzyme increased incidence and gastrointestinal adverse reactions in three groups of patients was no significant difference in the incidence rate after treated 4 weeks and 8 weeks (P> 0.05), no significant differen-ce between the three groups (P> 0.05).
Conclusion:Zhibitai combined with atorvastatin lOmg in patients with coronary heart disease can be significantly reduced TG, TC, LDL-C, ApoB100 level, slightly elevated HDL-C, ApoA1 levels and significantly reduce the inflammatory cytokines CT-1, hs-CRP levels, efficacy and similar atorvastatin 40mg, atorvastatin 20mg compared with more advantages and fewer side effects, clinical application security, is expected to become the new trend for future lipid-lowering therapy.
引文
1、王中平,刘凡,王玲,杨雅娟血脂异常与冠心病研究进展。四川解剖学杂志2010,18(3)：45-48
2、Benn M. A polipoprotein B 1 evel s, ApoB alleles, and risk of isch emic cardiovascular disease in the general popul at ion, areview [J]. Atheros clerosis, 2009,206(1):17-30.
3、Kriszbacher I, Koppan M, Bodis J. Inflammation, atheroscl erosis, and coronary artery disease [J]. N Engl J Med,2005,353 (4):429-430
4、包春辉血脂异常与冠状动脉粥样硬化斑块相关分析。中国社区医师医学专业半月刊2009,11(206)：22
5、杨俊丽,陈凤英冠心病的致病危险因素及预防。实用心脑肺血管病杂志2010,18(7)：1014-1015
6、Jorge Plutzky. The vascular biology of atherosclerosis. Am J Med,2003, 115:55-61
7、王京燕,李学信,屈艳玲,李小娜LDL-C/HDL-C、apoB/apoA1比值与冠心病的相关分析。中西医结合心脑血管病杂志2010,8(12)：1421-1422
8、易朝阳,游其勇高敏性CRP在心血管疾病中的应用[J]。医学检验与临床2009,20(2)：81-82.
9、范秋,张丽敏冠心病的临床诊断及治疗分析。中国医学创新2010,7(1)：57
10、Pennica D, King KI, Shaw KJ Expression cloning of cardiotrophin-1,acytokine that induces cardiac myocyte hypertrophy[J]. Proc Natl Acad Sci USA,1995,92 (4):1142
11、陈淑芬、姚震CT-1对心血管系统的生物学效应与心脏重塑的关系。岭南心血管病杂志2004,10(3)：222-225
12、Thygesen K. Alpert JS, white. Joint ESC/ACCF/AHA/IflIF Task Force for the Redefinition of Myocardial Infarction. Eur Heart.2007,28 (20):2525—2538
13、Talwar S, Squire IB, Downie PF, Plasma N terminal pro brain natriuretic peptide and cardiotrophin-1 are raised in unstable angina. Heart 2000,84:421-424.
14、史晓静,陶贵周不同剂量阿托伐他汀对老年冠心病合并心房颤动患者炎症因子及预后的影响。临床荟萃2010,25(7)：560-562
15、Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy [J]. Curr Med Res Opin,2003,19 (6):540-556
16、施志云他汀类药物临床应用研究进展[J]中国疗养医2010,19(2)：146
17、姚立枫他汀类药物安全性研究进展。天津药学2010,22(2)：72-74
18、天然他汀一枝独秀中华医学信息导报2003.18(12)：15
19、姚菁华,王珏,肖雷红曲霉中降脂活性物质的研究进展。安徽农业科学2008,6(24)：10524-10526
20、赵宇红,许丹焰,赵水平,黄艳红中药他汀类药物的研究进展。长治医学院学报2011,25(1)：74-77
21、颜景信冠心病不稳定型心绞痛患者C-反应蛋白临床意义。中国现代医生2010,48(19)：137-138
22、Jorge Plutzky The vascular biology of atherosclerosis Am J Med.2003, 115:55-61
23、汤益坤阿托伐他汀对不稳定心绞痛患者黏附分子和C反应蛋白的影响。实用预防医学2010,17(6)：1187-1188
24、金鑫,李拥军 他汀类药物在心血管疾病中应用的研究进展。临床荟萃2010,25(1)：86-86
25、闫晓英,赵喜娟强化阿托伐他汀对急性冠脉综合征C反应蛋白及血脂的影响。心血管康复医学杂志2010,19(3)：276-278
26、贾圣英,黄全跃,周祁娜脂必泰与阿托伐他汀的调脂疗效及对血管内皮功能影响。临床心血管病杂志2010,26(12)：909-911
27、许丹焰,舒君,黄全跃,陈琛,刘玲,赵水平脂必泰胶囊与阿托伐他汀疗效及安全性评估。中华内科杂志2010,20：14
28、周祁娜脂必泰胶囊与阿托伐他汀治疗心血管高危患者的对比研究。中南大学硕士学位论文2009,5
29、舒君 强化脂必泰治疗对血脂异常的冠心病中、高危患者炎症因子的影响及其安全性评估。中南大学硕士学位论文2009,5
30、张小玲,朱珉,叶青,周俊岭,严激阿托伐他汀治疗急性冠脉综合征患者血脂水平和超敏C-反应蛋白的变化。安徽医药2010,14(10)：1206-1207
31、罗秀英,张松心肌营养素-1在心血管疾病中的作用及进展。心血管病学进展2009,30：59-61
32、Talwar S, Squire I B. O'Brien RJ Plasma cardiotrophin-I following acutemyocardial infarction:relationship with left ventricular systolic dysfunctiota C1 inical Science.2002,102 (1):9-4
33、王岱岱促心肌素-1与急性冠脉综合征相关性研究。贵阳中医学院硕士学位论文2009,6
34、杨明栋,翟晓江,王予凯,丁汉元,任文丽,米绍妍,秦志慧,彭云莲,黄荔高敏C反应蛋白与冠心病关系的临床研究。中国当代医学2010,17(36)：181
35、王卫明C反应蛋白的研究进展。心血管病学进展2005,26(1)：73-75
36、吉宁飞、吉佑华、吉卫华、何畏、陈定阿托伐他汀对高脂血症者高敏C反应蛋白的影响及其调脂疗效和安全性评估。实用老年医学2009,23(1)：19-22
1、陈灏珠 实用内科学。第10版：1218-1219
2、金鑫,李拥军 他汀类药物在心血管疾病中应用的研究进展。临床荟萃2010,25(1)：86-89
3、姚菁华,王珏,肖雷 红曲霉中降脂活性物质的研究进展。安徽农业科学2008,36(24)：10524-10526
4、天然他汀一枝独秀 中华医学信息导报2003,18(12)：15
5、邢旺兴,张梅,方琅,邹晓华,郑筱祥 中药红曲的药理作用研究进展。药学实践杂志2006,24(1)：1-3
6、洪智勇,毛宁 红曲霉降TC有效成分的研究。海峡药学2002,14(1)：33-35
7、Maron DJ,Fazio S,Linton MF. current perspectives on statins.Circulation [J]. 2000,101(2):207-213.
8、李莉,翟晓娟,郭任维 血脂康阿托伐他汀对急性冠状动脉综合征短期抗炎作用的比较。中国药物与临床2010,10(5)：586-587
9、王文宏 血脂康和阿托伐他汀治疗高胆固醇血症的疗效比较。实用中医内科杂志2006,20(3)：305
10、王玉梅,李香超 血脂康治疗老年低高密度脂蛋白血症对照研究。临床医学2008,28(3)：51-52
11、程艳春,刘玲,赵水平,李玉玲 血脂康改善冠心病患者餐后高TG血症。中国循环杂志2003,18(4)：276-279
12、王旭玲,胡先明 血脂康与辛伐他汀对高TG血症调脂作用的比较。中西医结合心脑血管病杂志2004,2(6)：319-320
13、许丹焰,舒君,黄全跃,陈琛,刘玲,赵水平 脂必泰胶囊与阿托伐他汀疗效及安全性评估。中华内科杂志2010,20：14
14、血脂康调整血脂对冠心病二级预防研究协作组 中国冠心病二级预防研究。中华心血管杂志2005.33(2)：109-115
15、王丽,褚艳丽,陈梅 血脂康治疗非ST抬高的急性冠脉综合症55例疗效观察。牡丹江医学院学报2009,30(3)：51-52
16、朱云刊,李艳 血脂康治疗不稳定型心绞痛的临床观察。中国医药导报2008,5(31)：63-64
17、陆宗良,杜保民,陈祚,武阳丰,于学海,赵宇程中国冠心病二级预防研究——对合并糖尿病患者的干预结果分析。中华心血管病杂志 2005,33(12)：1067-1070
18、迟家敏北京医院(100730)血脂康对冠心病合并糖尿病的干预研究——“中国冠心病二级预防研究”糖尿病亚组分析。实用糖尿病杂志2006,2(3)：13-14
19、顾秀莲,樊济海,巢胜吾,刘宏鸣,王玲,彭华 血脂康对高血压合并冠心病患者135例脉压的改善作用。中国老年学杂志2010,30(7)：996-997
20、杜保民,陆宗良,陈柞,武阳丰 血脂康对合并高血压患者的冠心病二级预防作用。中华心血管病杂志2006,34(10)：890-894
21、杜保民,陆宗良,武阳丰,叶平,陈祚中国冠心病二级预防研究——老年高血压人群的干预结果分析。中华老年心血管病杂志2006,8(2)：82-86
22、血脂康调整血脂对冠心病二级预防研究协作组中国冠心病二级预防研究。中华心血管病杂志2005,33(2)：109-115
23、Hong M Y, Seeram N P, Zhang Y, et al. anticancer effects of chinese red yeast rice versus moncolin K alone on colon cancer cells. J Nutr Biochem.2007,19 (7):448-458
24、杨钟,赵君贤,张英鸽 血脂康胶囊的体外抗肿瘤作用。中医杂志2008,49(11)：1019-1022
25、闫晓英,赵喜娟 强化阿托伐他汀对急性冠脉综合征C反应蛋白及血脂的影响。心血管康复医学杂志2010,19(3)：276-278
26、张荃钦,姚光辉,朱红梅血脂康影响冠心病患者血清高敏C反应蛋白水平的临床研究。临床医药实践2010,19(1)：76-77
27、杨海波,唐元升,许法运,张兴华,朱兴雷 血脂康对高脂血症患者血管内皮功能及血中一氧化氮与内皮素水平的影响。中国中西医结合杂志2003,23(1)：13-15
28、程艳春,赵水平,刘玲,刘明辉,李玉玲 调脂治疗对冠心病患者餐后血管内皮功能的影响。中华心血管病杂志2004,32(2)：114-117
29、彭艳 血脂康对慢性心力衰竭患者TNF-a和IL-6及其血管内皮功能的影响。重庆医科大学硕士学位论文2009,5
2、Benn M. A polipoprotein B 1 evel s, ApoB alleles, and risk of isch emic cardiovascular disease in the general popul at ion, areview [J]. Atheros clerosis, 2009,206(1):17-30.
3、Kriszbacher I, Koppan M, Bodis J. Inflammation, atheroscl erosis, and coronary artery disease [J]. N Engl J Med,2005,353 (4):429-430
4、包春辉血脂异常与冠状动脉粥样硬化斑块相关分析。中国社区医师医学专业半月刊2009,11(206)：22
5、杨俊丽,陈凤英冠心病的致病危险因素及预防。实用心脑肺血管病杂志2010,18(7)：1014-1015
6、Jorge Plutzky. The vascular biology of atherosclerosis. Am J Med,2003, 115:55-61
7、王京燕,李学信,屈艳玲,李小娜LDL-C/HDL-C、apoB/apoA1比值与冠心病的相关分析。中西医结合心脑血管病杂志2010,8(12)：1421-1422
8、易朝阳,游其勇高敏性CRP在心血管疾病中的应用[J]。医学检验与临床2009,20(2)：81-82.
9、范秋,张丽敏冠心病的临床诊断及治疗分析。中国医学创新2010,7(1)：57
10、Pennica D, King KI, Shaw KJ Expression cloning of cardiotrophin-1,acytokine that induces cardiac myocyte hypertrophy[J]. Proc Natl Acad Sci USA,1995,92 (4):1142
11、陈淑芬、姚震CT-1对心血管系统的生物学效应与心脏重塑的关系。岭南心血管病杂志2004,10(3)：222-225
12、Thygesen K. Alpert JS, white. Joint ESC/ACCF/AHA/IflIF Task Force for the Redefinition of Myocardial Infarction. Eur Heart.2007,28 (20):2525—2538
13、Talwar S, Squire IB, Downie PF, Plasma N terminal pro brain natriuretic peptide and cardiotrophin-1 are raised in unstable angina. Heart 2000,84:421-424.
14、史晓静,陶贵周不同剂量阿托伐他汀对老年冠心病合并心房颤动患者炎症因子及预后的影响。临床荟萃2010,25(7)：560-562
15、Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy [J]. Curr Med Res Opin,2003,19 (6):540-556
16、施志云他汀类药物临床应用研究进展[J]中国疗养医2010,19(2)：146
17、姚立枫他汀类药物安全性研究进展。天津药学2010,22(2)：72-74
18、天然他汀一枝独秀中华医学信息导报2003.18(12)：15
19、姚菁华,王珏,肖雷红曲霉中降脂活性物质的研究进展。安徽农业科学2008,6(24)：10524-10526
20、赵宇红,许丹焰,赵水平,黄艳红中药他汀类药物的研究进展。长治医学院学报2011,25(1)：74-77
21、颜景信冠心病不稳定型心绞痛患者C-反应蛋白临床意义。中国现代医生2010,48(19)：137-138
22、Jorge Plutzky The vascular biology of atherosclerosis Am J Med.2003, 115:55-61
23、汤益坤阿托伐他汀对不稳定心绞痛患者黏附分子和C反应蛋白的影响。实用预防医学2010,17(6)：1187-1188
24、金鑫,李拥军 他汀类药物在心血管疾病中应用的研究进展。临床荟萃2010,25(1)：86-86
25、闫晓英,赵喜娟强化阿托伐他汀对急性冠脉综合征C反应蛋白及血脂的影响。心血管康复医学杂志2010,19(3)：276-278
26、贾圣英,黄全跃,周祁娜脂必泰与阿托伐他汀的调脂疗效及对血管内皮功能影响。临床心血管病杂志2010,26(12)：909-911
27、许丹焰,舒君,黄全跃,陈琛,刘玲,赵水平脂必泰胶囊与阿托伐他汀疗效及安全性评估。中华内科杂志2010,20：14
28、周祁娜脂必泰胶囊与阿托伐他汀治疗心血管高危患者的对比研究。中南大学硕士学位论文2009,5
29、舒君 强化脂必泰治疗对血脂异常的冠心病中、高危患者炎症因子的影响及其安全性评估。中南大学硕士学位论文2009,5
30、张小玲,朱珉,叶青,周俊岭,严激阿托伐他汀治疗急性冠脉综合征患者血脂水平和超敏C-反应蛋白的变化。安徽医药2010,14(10)：1206-1207
31、罗秀英,张松心肌营养素-1在心血管疾病中的作用及进展。心血管病学进展2009,30：59-61
32、Talwar S, Squire I B. O'Brien RJ Plasma cardiotrophin-I following acutemyocardial infarction:relationship with left ventricular systolic dysfunctiota C1 inical Science.2002,102 (1):9-4
33、王岱岱促心肌素-1与急性冠脉综合征相关性研究。贵阳中医学院硕士学位论文2009,6
34、杨明栋,翟晓江,王予凯,丁汉元,任文丽,米绍妍,秦志慧,彭云莲,黄荔高敏C反应蛋白与冠心病关系的临床研究。中国当代医学2010,17(36)：181
35、王卫明C反应蛋白的研究进展。心血管病学进展2005,26(1)：73-75
36、吉宁飞、吉佑华、吉卫华、何畏、陈定阿托伐他汀对高脂血症者高敏C反应蛋白的影响及其调脂疗效和安全性评估。实用老年医学2009,23(1)：19-22
1、陈灏珠 实用内科学。第10版：1218-1219
2、金鑫,李拥军 他汀类药物在心血管疾病中应用的研究进展。临床荟萃2010,25(1)：86-89
3、姚菁华,王珏,肖雷 红曲霉中降脂活性物质的研究进展。安徽农业科学2008,36(24)：10524-10526
4、天然他汀一枝独秀 中华医学信息导报2003,18(12)：15
5、邢旺兴,张梅,方琅,邹晓华,郑筱祥 中药红曲的药理作用研究进展。药学实践杂志2006,24(1)：1-3
6、洪智勇,毛宁 红曲霉降TC有效成分的研究。海峡药学2002,14(1)：33-35
7、Maron DJ,Fazio S,Linton MF. current perspectives on statins.Circulation [J]. 2000,101(2):207-213.
8、李莉,翟晓娟,郭任维 血脂康阿托伐他汀对急性冠状动脉综合征短期抗炎作用的比较。中国药物与临床2010,10(5)：586-587
9、王文宏 血脂康和阿托伐他汀治疗高胆固醇血症的疗效比较。实用中医内科杂志2006,20(3)：305
10、王玉梅,李香超 血脂康治疗老年低高密度脂蛋白血症对照研究。临床医学2008,28(3)：51-52
11、程艳春,刘玲,赵水平,李玉玲 血脂康改善冠心病患者餐后高TG血症。中国循环杂志2003,18(4)：276-279
12、王旭玲,胡先明 血脂康与辛伐他汀对高TG血症调脂作用的比较。中西医结合心脑血管病杂志2004,2(6)：319-320
13、许丹焰,舒君,黄全跃,陈琛,刘玲,赵水平 脂必泰胶囊与阿托伐他汀疗效及安全性评估。中华内科杂志2010,20：14
14、血脂康调整血脂对冠心病二级预防研究协作组 中国冠心病二级预防研究。中华心血管杂志2005.33(2)：109-115
15、王丽,褚艳丽,陈梅 血脂康治疗非ST抬高的急性冠脉综合症55例疗效观察。牡丹江医学院学报2009,30(3)：51-52
16、朱云刊,李艳 血脂康治疗不稳定型心绞痛的临床观察。中国医药导报2008,5(31)：63-64
17、陆宗良,杜保民,陈祚,武阳丰,于学海,赵宇程中国冠心病二级预防研究——对合并糖尿病患者的干预结果分析。中华心血管病杂志 2005,33(12)：1067-1070
18、迟家敏北京医院(100730)血脂康对冠心病合并糖尿病的干预研究——“中国冠心病二级预防研究”糖尿病亚组分析。实用糖尿病杂志2006,2(3)：13-14
19、顾秀莲,樊济海,巢胜吾,刘宏鸣,王玲,彭华 血脂康对高血压合并冠心病患者135例脉压的改善作用。中国老年学杂志2010,30(7)：996-997
20、杜保民,陆宗良,陈柞,武阳丰 血脂康对合并高血压患者的冠心病二级预防作用。中华心血管病杂志2006,34(10)：890-894
21、杜保民,陆宗良,武阳丰,叶平,陈祚中国冠心病二级预防研究——老年高血压人群的干预结果分析。中华老年心血管病杂志2006,8(2)：82-86
22、血脂康调整血脂对冠心病二级预防研究协作组中国冠心病二级预防研究。中华心血管病杂志2005,33(2)：109-115
23、Hong M Y, Seeram N P, Zhang Y, et al. anticancer effects of chinese red yeast rice versus moncolin K alone on colon cancer cells. J Nutr Biochem.2007,19 (7):448-458
24、杨钟,赵君贤,张英鸽 血脂康胶囊的体外抗肿瘤作用。中医杂志2008,49(11)：1019-1022
25、闫晓英,赵喜娟 强化阿托伐他汀对急性冠脉综合征C反应蛋白及血脂的影响。心血管康复医学杂志2010,19(3)：276-278
26、张荃钦,姚光辉,朱红梅血脂康影响冠心病患者血清高敏C反应蛋白水平的临床研究。临床医药实践2010,19(1)：76-77
27、杨海波,唐元升,许法运,张兴华,朱兴雷 血脂康对高脂血症患者血管内皮功能及血中一氧化氮与内皮素水平的影响。中国中西医结合杂志2003,23(1)：13-15
28、程艳春,赵水平,刘玲,刘明辉,李玉玲 调脂治疗对冠心病患者餐后血管内皮功能的影响。中华心血管病杂志2004,32(2)：114-117
29、彭艳 血脂康对慢性心力衰竭患者TNF-a和IL-6及其血管内皮功能的影响。重庆医科大学硕士学位论文2009,5